The incidence of oral herpes simplex virus infection in patients undergoing cancer chemotherapy
作者： Michael T. Montgomery , Spencer W. Redding , Charles F. LeMaistre
DOI: 10.1016/0030-4220(86)90368-3
关键词: Complication 、 Virus 、 Viral disease 、 Herpes simplex virus 、 Incidence (epidemiology) 、 Immunology 、 Chemotherapy 、 Internal medicine 、 Medicine 、 Immunosuppression 、 Antibody titer
摘要: Oral lesions in twenty-nine immunocompromised patients were evaluated for the incidence of herpes simplex virus (HSV) infections during either cancer chemotherapy or plus bone marrow transplantation (BMT). Patients' HSV antibody titers not determined, and positive diagnoses based solely on results viral cultures. Fourteen (48%) found to have herpetic infections, which is comparable with rates 50% 90% antibody-positive 40% mixed populations reported medical literature. However, this finding conflict 10.7% 15.1% rate cited dental literature undergoing chemotherapy. This underestimation believed reflect insensitivity criteria used diagnosis these studies.
elsevier.com
sci-hub.se 参考文章(17)
S L Spruance, Pathogenesis of herpes simplex labialis: excretion of virus in the oral cavity. Journal of Clinical Microbiology. ,vol. 19, pp. 675- 679 ,(1984) , 10.1128/JCM.19.5.675-679.1984
J. C. Wade, L. M. Day, J. J. Crowley, J. D. Meyers, Recurrent Infection with Herpes Simplex Virus after Marrow Transplantation: Role of the Specific Immune Response and Acyclovir Treatment The Journal of Infectious Diseases. ,vol. 149, pp. 750- 756 ,(1984) , 10.1093/INFDIS/149.5.750
J. D. Meyers, N. Flournoy, E. D. Thomas, Infection with herpes simplex virus and cell-mediated immunity after marrow transplant The Journal of Infectious Diseases. ,vol. 142, pp. 338- 346 ,(1980) , 10.1093/INFDIS/142.3.338
Joel D. Meyers, James C. Wade, Charles D. Mitchell, Rein Saral, Paul S. Lietman, David T. Durack, Myron J. Levin, Anthony C. Segreti, Henry H. Balfour, Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host The American Journal of Medicine. ,vol. 73, pp. 229- 235 ,(1982) , 10.1016/0002-9343(82)90097-3
JAMES C. WADE, Intravenous Acyclovir to Treat Mucocutaneous Herpes Simplex Virus Infection After Marrow Transplantation Annals of Internal Medicine. ,vol. 96, pp. 265- 269 ,(1982) , 10.7326/0003-4819-96-3-265
C. Stuart-Harris, The epidemiology and clinical presentation of herpes virus infections Journal of Antimicrobial Chemotherapy. ,vol. 12, pp. 1- 8 ,(1983) , 10.1093/JAC/12.SUPPL_B.1
I M Hann, H G Prentice, H A Blacklock, M G Ross, D Brigden, A E Rosling, C Burke, D H Crawford, W Brumfitt, A V Hoffbrand, Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial. BMJ. ,vol. 287, pp. 384- 388 ,(1983) , 10.1136/BMJ.287.6389.384
Samuel Dreizen, Gerald P. Bodey, Manuel Valdivieso, Chemotherapy-associated oral infections in adults with solid tumors Oral Surgery, Oral Medicine, Oral Pathology. ,vol. 55, pp. 113- 120 ,(1983) , 10.1016/0030-4220(83)90164-0
S.Gary Cohen, Martin S. Greenberg, Chronic oral herpes simplex virus infection in immunocompromised patients. Oral Surgery, Oral Medicine, Oral Pathology. ,vol. 59, pp. 465- 471 ,(1985) , 10.1016/0030-4220(85)90085-4
E. Gluckman, J. Lotsberg, A. Devergie, X. M. Zhao, R. Melo, M. Gomez-Morales, M. C. Mazeron, Y. Perol, Oral acyclovir prophylactic treatment of herpes simplex infection after bone marrow transplantation Journal of Antimicrobial Chemotherapy. ,vol. 12, pp. 161- 167 ,(1983) , 10.1093/JAC/12.SUPPL_B.161